Law Offices of Thomas J. Lamb

  • About Firm
  • Practice Areas
  • Free Case Evaluation
  • Quick Contact Form
  • Frequently Asked Questions
  • Attorney Tom Lamb

FDA Fast Tracks UV1, Ipilimumab, and Nivolumab in Malignant Mesothelioma

February 8, 2024 By Law Offices of Thomas J. Lamb, P.A.

The FDA has granted a fast track designation to the combination of UV1 with ipilimumab and nivolumab for the treatment of patients with unresectable malignant pleural mesothelioma. This regulatory decision is supported by findings from the phase 2 NIPU trial which is evaluating UV1 in patients with unresectable malignant pleural mesothelioma. … [Read more...]

Filed Under: Mesothelioma Tagged With: ipilimumab, malignant pleural mesothelioma (MPM), mesothelioma, mesothelioma treatments, nivolumab, pleural mesothelioma, UV1

Niraparib plus Dostarlimab in Pleural Mesothelioma or Non-Small Cell Lung Cancer harboring HRR mutations: interim results of the UNITO-001 phase 2 prospective trial

January 23, 2024 By Law Offices of Thomas J. Lamb, P.A.

Introduction: Treatment of homologous recombination repair deficient (HRD)-tumours with PARP inhibitors has the potential to further increase tumour immunogenicity, suggesting a synergistic effect with immunotherapy. Here we present the preliminary results of niraparib in combination with dostarlimab for pleural mesothelioma (PM) or non-small cell … [Read more...]

Filed Under: Mesothelioma Tagged With: mesothelioma, mesothelioma treatments, nira, pleural mesothelioma

Toxicities Potentially Linked to Combination Immunotherapy for Mesothelioma

January 12, 2024 By Law Offices of Thomas J. Lamb, P.A.

The [ immunotherapy combination ] of ipilimumab and nivolumab may result in a higher levels of toxicities in patients with unresectable pleural mesothelioma than was reported in the CheckMate 743 trial, according to a recent study published by McNamee et al in the Journal of Thoracic Oncology. Background: Australia has one of the highest rates … [Read more...]

Filed Under: Mesothelioma Tagged With: mesothelioma, mesothelioma treatments, pleural mesothelioma

Pembrolizumab Plus Lenvatinib as Second- and Third-Line Treatments of Pleural Mesothelioma

October 31, 2023 By Law Offices of Thomas J. Lamb, P.A.

In a Dutch single-institution phase II trial (PEMMELA) reported in The Lancet Oncology, Douma et al found that the combination of pembrolizumab and lenvatinib showed activity as second- and third-line treatments of patients with pleural mesothelioma. Study Details A total of 38 evaluable patients with disease progression after … [Read more...]

Filed Under: Mesothelioma Tagged With: mesothelioma, mesothelioma treatments, pleural mesothelioma

Pembrolizumab plus lenvatinib in second-line and third-line patients with pleural mesothelioma (PEMMELA): a single-arm phase 2 study

October 17, 2023 By Law Offices of Thomas J. Lamb, P.A.

Background:  The combination of pembrolizumab, an anti-PD-1 antibody, and lenvatinib, an antiangiogenic multikinase inhibitor, shows synergistic activity in preclinical and clinical studies in solid tumours. We assessed the clinical activity of this combination therapy in patients with pleural mesothelioma who progressed after platinum-pemetrexed … [Read more...]

Filed Under: Mesothelioma Tagged With: mesothelioma treatments, pleural mesothelioma

Pleural Mesothelioma: A Rapid Evolution of an Indolent Disease

January 31, 2023 By Law Offices of Thomas J. Lamb, P.A.

Mesothelioma is a rare and insidious neoplasm and is characterized by its highly malignant and aggressive nature. The most common etiology is asbestos exposure, but there are some reports without known asbestos exposure and other factors leading to malignant pleural mesothelioma (MPM). Here, we present the case of a 58-year-old woman with … [Read more...]

Filed Under: Asbestos, Mesothelioma Tagged With: asbestos exposure, malignant pleural mesothelioma (MPM), mesothelioma, pleural mesothelioma

Preoperative immunotherapy for mesothelioma shows favorable outcomes

December 16, 2022 By Law Offices of Thomas J. Lamb, P.A.

In a study published recently in the journal Clinical Cancer Research, researchers at Baylor College of Medicine found that treating patients who have resectable malignant pleural mesothelioma, meaning that their tumor can be removed with surgery, with immunotherapy [ with immune checkpoint inhibitors ] ahead of surgery resulted in favorable … [Read more...]

Filed Under: Mesothelioma Tagged With: mesothelioma, mesothelioma treatments, pleural mesothelioma

  • « Previous Page
  • 1
  • 2

Find What You Want Here

Get Free Case Evaluation

We encourage you to submit an online Case Evaluation Form – it is confidential and there is no obligation.

Or call our toll-free number, 800-426-9535, to speak directly to attorney Tom Lamb about your possible case.

Feel Free To Contact Us

Quick Contact Form
 
Send an Email to Tom Lamb

(800) 426-9535

Main Navigation Menu

  • About Firm
  • Asbestos-Mesothelioma Cases
  • Benzene Disease Claims
  • Drug Injury Lawsuits
  • Breast Implant Cancer Cases
  • Case Evaluation Menu
  • Quick Contact Form
  • Frequently Asked Questions
  • Medical Records Charges
  • Collection of Articles
  • Sitemap

Lamb Law Office Newsletter

Lamb Law Office Newsletter provides periodic updates about some of the cases that we are working on for clients, as well as an information resource you might find helpful.

Subscribe using Form below.

Subscription Form

* indicates required

Our Other Websites

DrugInjuryLaw.com

DrugInjuryWatch.com

Asbestos-Mesothelioma.com

Contact Information

Law Offices of Thomas J. Lamb, P.A.
1908 Eastwood Road, Suite 225
Wilmington, North Carolina 28403
910-256-2971 | 800-426-9535
TJL@LambLawOffice.com

  • Home
  • Disclaimer and Copyright Notices
  • Sitemap

Copyright © 2025 · Law Offices of Thomas J. Lamb, P.A.